Episode 118

What's the Holdup? - Part 2 (Episode 118)

Guest: Kent New

Welcome back to our second episode in this three-part series about the barriers to progress for spinal cord injury treatments. We’re once again joined by neurosurgeon, researcher and lived-experience advocate, Dr. Kent New. In this episode, we discuss the problems associated with preclinical, as well as early- and late-stage clinical trials. If you missed it, you can check out part 1 in this series here.

Listen on: Spotify | Apple Podcasts | Soundcloud

Bumper music: Dig a Hole by Freaque

Guest Bio

Dr. Kent New, from Alexandria, Virginia, obtained a BA in Chemistry at the University of Virginia in 1989. He entered an MD/PhD program at Georgetown University, earning his PhD in Microbiology and Immunology. In 1998, Dr. New began residency training in Neurosurgery at Duke University where he also completed a funded research fellowship in tumor immunology. From 2005-08, Dr. New worked at Mayo Clinic in Jacksonville specializing in brain tumor research and clinical work. In 2008, Dr. New moved to Ascension St Vincent’s Southside hospital where he pursued private practice until suffering a C6 spinal cord injury in a MVA in late 2014.

Dr. New currently oversees clinical research at St Vincent’s neurosurgery, serves on the board of directors for the Brain Tumor Network and a retirement community, and recently joined SCOPE and the expert committee for scitrialfinder.net to broaden his involvement in the SCI community.